Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $9.68 Analyst target: $32.50 Upside: 235.74%
SELLAS Life Sciences Group, Inc., an advanced-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for various indications of cancer in the United States. The company is headquartered in New York, New York.
See the full interactive analysis & chart →Informational only — not investment advice.